MAPT and Alzheimer disease: Even though SUMOylation may exert neuroprotective functions [923], a dysregulated SUMO system can also negatively impact Aβ and tau aggregates in AD [924] due to the fact that SUMOylation not only controls protein–protein interactions [886] but also regulates the transcriptional control of RNA through various post-transcriptional modifications [925].